Investors

Growing Shareholder Value

Press Releases

Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA

Nov 19, 2019
Read More

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

Nov 14, 2019
Read More

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Oct 31, 2019
Read More

Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin

Oct 31, 2019
Read More

FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Oct 25, 2019
Read More

Abiomed Second Quarter Fiscal 2020 Earnings and Conference Call Notification

Oct 10, 2019
Read More

Abiomed Announces 1,000th Patient Treated with Impella in Japan

Oct 07, 2019
Read More

Study Demonstrates Early Use of Impella Can Increase Survival in Cardiogenic Shock; Escalation Protocols Initiated

Sep 27, 2019
Read More

PROTECT III Presented at TCT 2019 – Clinical Data Demonstrates Protected PCI with Impella is Associated with Improved Outcomes

Sep 26, 2019
Read More

Abiomed Receives FDA PMA Approval for Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Sep 25, 2019
Read More
View all